Literature DB >> 22249440

Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability.

Jens Plaschke1, Mark Preußler, Andreas Ziegler, Hans K Schackert.   

Abstract

PURPOSE: High level of microsatellite instability (MSI-H) in colorectal cancer (CRC) is caused by the inactivation of mismatch repair (MMR) genes; however, it is unknown for tumors with low level MSI (MSI-L). The protein complex involving MSH3 preferentially recognizes insertion/deletion loops (IDLs) of two to eight bases and di- and tetranucleotide repeats are affected in the majority of MSI-L CRC.
METHODS: We selected 10 and eight MSI-L CRCs from 228 and 204 patients with sporadic and hereditary disease, respectively. The tumors were analyzed for protein expression of MSH3, MSH2, MSH6, MLH1, and PMS2, and for mutations and loss of heterozygosity (LOH) in MSH3.
RESULTS: Four tumors showed a markedly reduced MSH3 expression, whereas all 18 tumors had normal expression of the remaining MMR proteins. Twenty-five different sequence variants were identified. None of these results in a truncated protein, though L902W represents the first constitutional missense mutation in MSH3 predicted to be functional based on conservation among mutS homologues. All variants have also been found in normal DNA of the patients and in controls. LOH intragenic to MSH3 was evident for 12 of 16 (75%) informative tumors.
CONCLUSIONS: Occurrence of sequence variants in normal DNA of the patients and in controls excludes somatic mutations and mutations specific to the CRC patient population, respectively. In contrast, the high frequency of LOH as well as the aberrant protein expression in some tumors indicates an involvement of MSH3 impairment in MSI-L CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249440     DOI: 10.1007/s00384-011-1408-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  51 in total

1.  hMSH3 and hMSH6 interact with PCNA and colocalize with it to replication foci.

Authors:  H E Kleczkowska; G Marra; T Lettieri; J Jiricny
Journal:  Genes Dev       Date:  2001-03-15       Impact factor: 11.361

Review 2.  The multifaceted mismatch-repair system.

Authors:  Josef Jiricny
Journal:  Nat Rev Mol Cell Biol       Date:  2006-05       Impact factor: 94.444

3.  Mutation rate in human microsatellites: influence of the structure and length of the tandem repeat.

Authors:  B Brinkmann; M Klintschar; F Neuhuber; J Hühne; B Rolf
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

4.  hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.

Authors:  S Acharya; T Wilson; S Gradia; M F Kane; S Guerrette; G T Marsischky; R Kolodner; R Fishel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 5.  Structure and function of the components of the human DNA mismatch repair system.

Authors:  Thomas Jascur; C Richard Boland
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

6.  MSH6 and MSH3 are rarely involved in genetic predisposition to nonpolypotic colon cancer.

Authors:  J Huang; S A Kuismanen; T Liu; R B Chadwick; C K Johnson; M W Stevens; S K Richards; J E Meek; X Gao; F A Wright; J P Mecklin; H J Järvinen; H Grönberg; M L Bisgaard; A Lindblom; P Peltomäki
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

7.  Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA.

Authors:  G Obmolova; C Ban; P Hsieh; W Yang
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

Review 8.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

9.  MSI-low, a real phenomenon which varies in frequency among cancer types.

Authors:  Sarah E R Halford; Elinor J Sawyer; Maryou B Lambros; Patricia Gorman; Nicola D Macdonald; Ian C Talbot; William D Foulkes; Cheryl E Gillett; Diana M Barnes; Lars A Akslen; Kwok Lee; Ian J Jacobs; Andrew M Hanby; Trivadi S Ganesan; Helga B Salvesen; Walter F Bodmer; Ian P M Tomlinson; Rebecca R Roylance
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

10.  Mutator phenotypes in human colorectal carcinoma cell lines.

Authors:  N P Bhattacharyya; A Skandalis; A Ganesh; J Groden; M Meuth
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

View more
  14 in total

1.  The landscape of microsatellite instability in colorectal and endometrial cancer genomes.

Authors:  Tae-Min Kim; Peter W Laird; Peter J Park
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

2.  The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair.

Authors:  J M M van Oers; Y Edwards; R Chahwan; W Zhang; C Smith; X Pechuan; S Schaetzlein; B Jin; Y Wang; A Bergman; M D Scharff; W Edelmann
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

3.  Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis.

Authors:  Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz
Journal:  Am J Hum Genet       Date:  2016-07-28       Impact factor: 11.025

4.  Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.

Authors:  Monika Morak; Sarah Käsbauer; Martina Kerscher; Andreas Laner; Anke M Nissen; Anna Benet-Pagès; Hans K Schackert; Gisela Keller; Trisari Massdorf; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  Aberrant methylation of the MSH3 promoter and distal enhancer in esophageal cancer patients exposed to first-hand tobacco smoke.

Authors:  Matjaz Vogelsang; Juliano D Paccez; Georgia Schäfer; Kevin Dzobo; Luiz F Zerbini; M Iqbal Parker
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-17       Impact factor: 4.553

6.  Detection of DNA repair protein in colorectal cancer of patients up to 50 years old can increase the identification of Lynch syndrome?

Authors:  Demétrius Eduardo Germini; Ana Maria Amaral Antônio Mader; Luiz Guilherme Lisboa Gomes; Thérèse Rachel Teodoro; Maria Isete Fares Franco; Jaques Waisberg
Journal:  Tumour Biol       Date:  2015-09-25

7.  How many diseases are colorectal cancer?

Authors:  A Greystoke; S A Mullamitha
Journal:  Gastroenterol Res Pract       Date:  2012-09-09       Impact factor: 2.260

8.  Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches.

Authors:  Ricardo Mouro Pinto; Ella Dragileva; Andrew Kirby; Alejandro Lloret; Edith Lopez; Jason St Claire; Gagan B Panigrahi; Caixia Hou; Kim Holloway; Tammy Gillis; Jolene R Guide; Paula E Cohen; Guo-Min Li; Christopher E Pearson; Mark J Daly; Vanessa C Wheeler
Journal:  PLoS Genet       Date:  2013-10-31       Impact factor: 5.917

Review 9.  Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome).

Authors:  Daniel D Buchanan; Christophe Rosty; Mark Clendenning; Amanda B Spurdle; Aung Ko Win
Journal:  Appl Clin Genet       Date:  2014-10-06

10.  Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities.

Authors:  Patrícia Silva; Cristina Albuquerque; Pedro Lage; Vanessa Fontes; Ricardo Fonseca; Inês Vitoriano; Bruno Filipe; Paula Rodrigues; Susana Moita; Sara Ferreira; Rita Sousa; Isabel Claro; Carlos Nobre Leitão; Paula Chaves; António Dias Pereira
Journal:  Int J Mol Med       Date:  2016-07-05       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.